COVIOS®AG


COVID-19 Antigen Rapid Diagnostic Test

JANUARY 2022	
REF 11811125	
FOR PROFESSIONAL USE	C€


Global
Access
Diagnostics

KIT COMPONENTS (ALL SINGLE USE ONLY)

- Lateral flow device
- Sterile swab
- Swab extraction buffer tube









MATERIALS REQUIRED BUT NOT PROVIDED


- Tube stand
- Stopwatch/ timer


PLEASE READ IN FULL


SPECIMEN COLLECTION AND HANDLING












CLOSE: Seal the

tube by pushing



INTERPRETATION OF TEST RESULTS

DO NOT
INTERPRET THE
TEST AFTER 15
MINUTES. IF
UNSURE, PLEASE
REPEAT TEST
ON NEW DEVICE
AND INTERPRET
AT 10 MINUTES



POSTIVE

THE TUBE

If the test line (T) is visible, this indicates a postive SARS-CoV-2 result.

If the test line (T) is faint, this indicates a postive SARS-CoV-2 result.

NEGATIVE

T C



If the test line (T) is not visible, this indicates a negative result.

INVALID

<u>Г</u>



If the control line (C) is absent, the test is invalid.

COVIOS® AG COVID-19 ANTIGEN RAPID DIAGNOSTIC TEST: PERFORMANCE DATA

Prospective Recruitment		RT-qPCR		
		Pos	Neg	Total
GAD Rapid Antigen Test	Pos	173	0	173
	Neg	18	458	476
	Total	191	458	649

Performance	Sensitivity	Specificity
	90.6% (85.6% to 94.0%)	100.0% (99.2% to 100.0%)

GAD COVID-19 Rapid Antigen Test uses a nose only (anterior nares) swab RT-qPCR platforms: TibMolbiol and Roche Range Ct. 11.7 to 34.7

Sensitivity stratified by RT-PCR cycle threshold value		
Ct	Sensitivity	
<20	100.0% (92/92)	
<25	96.4% (160/166)	
<33	92.5% (172/186)	

COVID-19 MICROBIAL INTERFERENCE AND CROSS REACTIVITY

Pathogen	Concentration stock TCID ₅₀ **Or CFU/mL	Reactive			
hCoV-OC-43	4.17 x 10 ⁵	No Cross-Reactivity			
hCoV-229-E	1.70 x 10 ⁵	No Cross-Reactivity			
hCoV-NL-63	1.41 x 10 ⁵	No Cross-Reactivity			
Adenovirus 5	1.30 x 10 ⁵	No Cross-Reactivity			
hMPV-16	1.26 x 10 ⁶	No Cross-Reactivity			
Parainfluenza 1	5.01 x 10 ⁵	No Cross-Reactivity			
Parainfluenza 2	1.51 x 10 ⁶	No Cross-Reactivity			
Parainfluenza 3	1.70 x 10 ⁵	No Cross-Reactivity			
Parainfluenza 4A	4.17 x 10 ⁵	No Cross-Reactivity			
Influenza A H3N2	1.41 x 10 ⁵	No Cross-Reactivity			
Influenza A H1N1	1.41 x 10 ⁵	No Cross-Reactivity			
Influenza B	1.26 x 10 ⁶	No Cross-Reactivity			
Enterovirus type 68	1.26 x 10 ⁶	No Cross-Reactivity			
RSV-A	5.01 x 10 ⁵	No Cross-Reactivity			
Rhinovirus type 1A	1.41 x 10 ⁵	No Cross-Reactivity			
Haemophilus influenza	5.43 x 10 ⁵	No Cross-Reactivity			
Streptococcus pneumoniae	4.16 x 10 ⁸	No Cross-Reactivity			
Streptococcus pyogenes	2.66 x 10 ⁹	No Cross-Reactivity			
Candida albicans	4.50 x 10 ⁸	No Cross-Reactivity			
Bordetella pertussis	6.43 x 10 ⁹	No Cross-Reactivity			
Legionella pneumophila	1.42 x 10 ¹⁰	No Cross-Reactivity			
Pneumocystis jiroveci	6.34 x 10 ⁸	No Cross-Reactivity			

INTENDED USE

The COVIOS®AG COVID-19 Antigen Rapid Diagnostic Test is a qualitative point of care, lateral Flow immunoassay and is used as an aid to the auglitative detection of SARS-CoV-2 antigens in human nasal swabs from individuals who are at risk or suspected of COVID-19 by their healthcare provider during the acute phase of infection. Test results should be considered in conjunction with other diagnostic and clinical information.

PRINCIPLES OF THE TEST

Nucleocapsid proteins in the sample are bound by capture reagents in the test lines as they are transported through the lateral flow strip, and made visible by secondary reagents.

A visible test line confirms the presence of the virus or fragment of the virus, indicating that the subject is experiencing COVID-19 infection.

The appearance of the CONTROL line (marked C) confirms that the test has been performed correctly.

STORAGE

This product is stable at room temperature $(2-30^{\circ}C)$.

WARNINGS & PRECAUTIONS

- · For in vitro diagnostic use only.
- Single use. Used tests must not be re-used.
- Do not use after the expiry date printed on the packaging.
- · Store at room temperature.
- Dispose of used kit components safely in clinical waste.
- Do not open pouch until you are ready to use the test. Use within 10 min of opening.

LIMITATIONS OF USE

- The COVIOS®AG COVID-19 Antigen Rapid Diagnostic Test is designed for use by medical professionals or trained personnel who are competent in administrating rapid antigen tests. Sample collection by selfswabbing is acceptable
- For reliable results, follow the instructions
- Test results should be used in conjunction with other clinical and patient information
- Positive test results do not rule out co-infections with other pathogens.
- Negative test results may occur if antigen levels extracted in a specimen are below the sensitivity of the test or sampled inappropriately.



If you have any questions or comments, please contact our helpline on +44 1234 619973 during UK office hours, or email info@globalaccessdiagnostics.com





Mologic Ltd, Bedford Technology Park, Thurleigh, Bedford MK44 2YA, UK



Advena Ltd. Tower Business Centre, 2nd Flr., Tower Street, Swatar, BKR 4013 Malta

FINDDX Ref: https://bit.ly/3nEeoi2